IC
RCUS icon

Ikarian Capital’s Arcus Biosciences RCUS Stock Holding History

Ikarian Capital’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-163,363
Closed -$1.33M – 189
2025
Q2 		$1.33M Hold
163,363
– – 0.26% 75
2025
Q1 		$1.28M Sell
163,363
-215,000
-57% -$2.49M 0.16% 84
2024
Q4 		$5.63M Sell
378,363
-365,637
-49% -$5.97M 0.77% 35
2024
Q3 		$11.4M Buy
744,000
+599,000
+413% +$9.44M 1.59% 13
2024
Q2 		$2.21M Buy
+145,000
New +$2.34M 0.38% 53
2023
Q4 		– Sell
-254,876
Closed -$4.07M – 168
2023
Q3 		$4.58M Sell
254,876
-25,124
-9% -$505K 0.55% 51
2023
Q2 		$5.69M Buy
280,000
+50,000
+22% +$952K 0.91% 35
2023
Q1 		$4.2M Buy
230,000
+92,013
+67% +$1.76M 0.95% 39
2022
Q4 		$2.85M Buy
+137,987
New +$3.8M 0.69% 38

Other funds holding RCUS

GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Ikarian Capital's RCUS Position: Q3 2025 in Review

Ikarian Capital sold out of Arcus Biosciences (RCUS) in Q3 2025, closing a stake of 163,363 shares — an estimated $1.33M sold.

Ikarian Capital first reported a position in RCUS in Q4 2022 and held it in 9 quarters. The position peaked at $11.4M in Q3 2024. 190 funds tracked by Wall St. Rank hold RCUS as of Q3 2025.

  • Ikarian Capital reported no remaining Arcus Biosciences position as of Q3 2025 after selling out during the quarter.
  • Ikarian Capital sold 163,363 Arcus Biosciences shares in Q3 2025, an estimated $1.33M.
  • Ikarian Capital first reported a position in Arcus Biosciences in Q4 2022 and held it in 9 quarters.
  • Ikarian Capital's Arcus Biosciences position peaked at $11.4M in Q3 2024.
  • 190 funds tracked by Wall St. Rank held Arcus Biosciences as of Q3 2025.

Based on Ikarian Capital's 13F filing for Q3 2025, filed 14 Nov 2025.